Nephros (NEPH) analyst forecast and price target
Analyst forecast
Consensus of 3 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Maxim Group | Maintained | Buy | $6.00 from $4.50 | Aug 8, 2025 |
| Benchmark | Maintained | Speculative Buy | $5.00 | Nov 12, 2024 |
| Benchmark | Maintained | Speculative Buy | $5.00 | May 15, 2024 |
| Benchmark | Upgraded | Hold → Speculative Buy | $5.00 | Mar 8, 2024 |
Frequently asked questions
Is NEPH a buy, sell, or hold?
Analysts covering Nephros currently average a Buy rating: 2 buy, 1 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on NEPH?
On Aug 8, 2025, Maxim Group maintained Nephros at Buy with a price target of $6.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.